Systemic sclerosis pts in the PRESS & STRIKE cohorts - High type I interferon (IFN) scores in diffuse SSc pts correl

Tweet Author

Tweet Content

Systemic sclerosis pts in the PRESS & STRIKE cohorts - High type I interferon (IFN) scores in diffuse SSc pts correlated w/ high disease activity & worse 12-month prognosis and overall survival. https://t.co/pdPjoVfQNH https://t.co/RB7li2ZIxX

Links

Serum type I interferon score as a disease activity biomarker in patients with … https://buff.ly/LuMERrt

10 April 2025

Should Lupus Nephritis Receive PJP Prophylaxis?

A current review article suggests that the need for Pneumocystis jirovecii pneumonia (PJP) prophylaxis in patients with systemic lupus erythematosus (SLE) and lupus nephritis will need to be individualized based on therapies and risk factors.

There are no clear guidelines for PJP prophylaxis in SLE and LN. But added use of immunosuppressive medications and systemic corticosteroids may change this consideration, especially since patients with autoimmune disease and PJP may have an estimated mortality of 40% to 50%.

MMWR: While PRE-overdose opioid prescribing is a risk marker for fatal overdose from opioids alone, stimulants alone, or

Tweet Author

RheumNow

Tweet Content

MMWR: While PRE-overdose opioid prescribing is a risk marker for fatal overdose from opioids alone, stimulants alone, or both; PRE-overdose stimulant prescribing might not be a risk marker for fatal overdose attributable to stimulants. https://t.co/ReVbpligeT https://t.co/PnjeqaCySX

Links

Controlled Substance Prescribing Patterns Among Fatal... https://buff.ly/on8fEkD

Diagnostically, Xrays are effective & sufficient at Diagnosing chronic low back pain; X-rays predicted MRI results i

Tweet Author

RheumNow

Tweet Content

Diagnostically, Xrays are effective & sufficient at Diagnosing chronic low back pain; X-rays predicted MRI results in approximately 75% of the cases for common low back pain problems suggesting they may be a preferred initial imaging study for this condition. https://t.co/PYzd1zXIRz

Inebilizumab, an anti-CD19+ (B cell)mAb was tested in myasthenia gravis in phase 3, 238 pt trial and shows to signif. im

Tweet Author

RheumNow

Tweet Content

Inebilizumab, an anti-CD19+ (B cell)mAb was tested in myasthenia gravis in phase 3, 238 pt trial and shows to signif. improv function and reduce disease severity in acetylcholine recpt Ab+ or muscle-specific kinase Ab+ myasthenia gravis pts. https://t.co/vBBjf8AUug https://t.co/cUbK4PJEvf

Links

A Phase 3 Trial of Inebilizumab in Generalized Myasthenia Gravis | NEJM https://buff.ly/Y5PBzWb

EMA's EudraVigilance (safety) database study of 10,319 MTX reports (age: 62 yrs, 73% F). Adverse rxns (ADR): 365 kidney

Tweet Author

RheumNow

Tweet Content

EMA's EudraVigilance (safety) database study of 10,319 MTX reports (age: 62 yrs, 73% F). Adverse rxns (ADR): 365 kidney & 1,082 liver related. MTX renal ADRs were older, w/ comeds (NSAIDs, Tylenol, metamizole, steroids). More deaths w/ renal ADRs than liver(21% vs 6%); mostly w/ https://t.co/tQ9PSOTtyx

EMA has approved upadacitinib (Rinvoq) for use in the EU to treat adult patients with giant cell arteritis (GCA) - appro

Tweet Author

RheumNow

Tweet Content

EMA has approved upadacitinib (Rinvoq) for use in the EU to treat adult patients with giant cell arteritis (GCA) - approval is based on data from the Phase 3 SELECT-GCA trial demonstrating sustained remission and key secondary endpoints https://t.co/Y2tyZPC9Et https://t.co/SHPz2Q94Vs

Links

AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the… https://buff.ly/GCUpORY

JAMA Staphylococcus aureus Review - s. aureus bacteremia leads to septic arthritis (7%), vertebral osteomyelitis (≈4%

Tweet Author

RheumNow

Tweet Content

JAMA Staphylococcus aureus Review - s. aureus bacteremia leads to septic arthritis (7%), vertebral osteomyelitis (≈4%) - bacteremia (≥48 hs) has 39% 90-day mortality risk https://t.co/1UQoz7JDPU https://t.co/xTAkakv2he

Links

Staphylococcus aureus Bacteremia: A Review https://buff.ly/mgZfeg4

185 children with SLE (cSLE) were analyze for long-term outcomes. 38 (20.54%) had serositis. Pts w/ serositis were you

Tweet Author

RheumNow

Tweet Content

185 children with SLE (cSLE) were analyze for long-term outcomes. 38 (20.54%) had serositis. Pts w/ serositis were younger, had more Dz activity, acomorbidities, & mortality. Having both serositis and ESRD increased risk of poor 20 Yr survival. https://t.co/fw8wcuS48E https://t.co/LgS3Sxy7gd

Links

Serositis as an indicator of poor prognosis in pediatric systemic lupus erythem… https://buff.ly/LesmY0p

EPIC EHR data assessed pre- & post-COVID. Pt messaging increased w/ pandemic & remained elevated, w/ no change i

Tweet Author

RheumNow

Tweet Content

EPIC EHR data assessed pre- & post-COVID. Pt messaging increased w/ pandemic & remained elevated, w/ no change in pt phone calls. MD EHR time/wk increased for all MDs, post COVID-19: (PCP +6.5%), subspecialists (+9.9%), surgeons (+5.2%). https://t.co/j8zwPkdmp9 https://t.co/SyYpZwnMfN

Links

Trends in Physician Electronic Health Record Time and Message Volume https://buff.ly/dE9wo79

Topics

Systemic sclerosis pts in the PRESS & STRIKE cohorts - High type I interferon (IFN) scores in diffuse SSc pts correl

MMWR: While PRE-overdose opioid prescribing is a risk marker for fatal overdose from opioids alone, stimulants alone, or

Diagnostically, Xrays are effective & sufficient at Diagnosing chronic low back pain; X-rays predicted MRI results i

Inebilizumab, an anti-CD19+ (B cell)mAb was tested in myasthenia gravis in phase 3, 238 pt trial and shows to signif. im

EMA's EudraVigilance (safety) database study of 10,319 MTX reports (age: 62 yrs, 73% F). Adverse rxns (ADR): 365 kidney

EMA has approved upadacitinib (Rinvoq) for use in the EU to treat adult patients with giant cell arteritis (GCA) - appro

JAMA Staphylococcus aureus Review - s. aureus bacteremia leads to septic arthritis (7%), vertebral osteomyelitis (≈4%

185 children with SLE (cSLE) were analyze for long-term outcomes. 38 (20.54%) had serositis. Pts w/ serositis were you

EPIC EHR data assessed pre- & post-COVID. Pt messaging increased w/ pandemic & remained elevated, w/ no change i

Do you get our email newsletter?